A central atypical cartilaginous tumor, often shortened to ACT, is a slow-growing tumor made of cartilage that develops inside a bone of the arms or legs. Central means it starts in the hollow center of the bone, where the bone marrow is.
This tumor sits between a noncancerous cartilage tumor called an enchondroma and a cartilage cancer called a chondrosarcoma. It can grow into the surrounding bone and can come back after treatment, but it rarely spreads to other parts of the body. For this reason, the World Health Organization places it in a middle category described as locally aggressive, rather than calling it a cancer.
Many atypical cartilaginous tumors cause no symptoms and are found by chance on an X-ray or MRI done for another reason. The outlook is excellent.
This article explains what an atypical cartilaginous tumor is, how it is diagnosed, and what the findings in your pathology report mean.
Under the microscope, an atypical cartilaginous tumor and a grade 1 chondrosarcoma look the same. The difference is where the tumor is, because location changes how it behaves:
You may see either name on older reports for a tumor in an arm or leg, because the term atypical cartilaginous tumor was introduced in 2013.
Many people have no symptoms. Doctors often find the tumor during imaging for an unrelated problem, such as a knee or shoulder injury.
When symptoms occur, the most common is a dull, aching pain in the affected bone. Some people notice swelling. New or worsening pain in a known cartilage tumor is a reason to have it checked, because it can signal that the tumor is growing.
For most people, doctors don’t find a cause. Many atypical cartilaginous tumors carry a change in a gene called IDH1 or IDH2. This change develops in the tumor during a person’s lifetime. It is not inherited and cannot be passed on to children.
People with many enchondromas (Ollier disease) or enchondromas with blood vessel growths (Maffucci syndrome) have a higher risk. Both conditions are caused by an IDH change that occurs early in development. They are not inherited.
X-rays and MRI usually show a cartilage tumor inside the bone, often with small flecks of calcium. Imaging is especially important for this diagnosis. Signs that the tumor is wearing away the inner surface of the bone or growing larger help separate it from an enchondroma.
A biopsy may be done, although many tumors are diagnosed from imaging and then removed without a separate biopsy. When a biopsy is done, it should be performed at the center that will provide treatment.
Under the microscope, an atypical cartilaginous tumor is made of cartilage cells arranged in rounded groups called lobules. The cells look only slightly abnormal. What separates it from an enchondroma is that the tumor grows into the spaces of the surrounding bone and surrounds the existing bone, rather than sitting beside it.
An atypical cartilaginous tumor and an enchondroma can look almost identical under the microscope, and small samples may not include the tumor edge where the difference is clearest. Pathologists and radiologists therefore make this diagnosis together, using the imaging as much as the microscope.
IDH testing does not help with this decision, because enchondromas carry the same change. It can help separate cartilage tumors from other bone tumors that look similar.
The distinction affects treatment only modestly, because both are often managed with careful observation or a limited operation. Your team will explain how the diagnosis shapes your plan.
Most atypical cartilaginous tumors are removed by scraping them out of the bone in a procedure called curettage. The tissue arrives in many pieces, so the pathologist cannot assess margins. Whether tumor remains is judged by the surgeon and by imaging after surgery.
When a tumor is removed in one piece, the report will list each margin and whether tumor reaches it. A positive margin raises the chance that the tumor will come back.
Bone tumors are staged using the TNM system from the American Joint Committee on Cancer (AJCC), 8th edition. For an atypical cartilaginous tumor in an arm or leg, the stage depends mainly on size. A tumor 8 cm or smaller is pT1, and a tumor larger than 8 cm is pT2.
Staging is often not included in the report for this tumor, especially after curettage. Lymph nodes are not involved and are not removed.
The outlook is excellent. Between about 87% and 99% of people are alive five years after diagnosis in published series, and deaths from this tumor are very rare.
These figures describe groups of people and cannot predict what will happen to one person.
Atypical cartilaginous tumors are best managed by a team experienced in bone tumors. Two main approaches exist, and the choice depends on tumor size, symptoms, and your preferences.
Chemotherapy and radiation therapy are not used for atypical cartilaginous tumors.